3Mahalati K,Belitsky P,Sketris I,et al.Neoral monitoring by simplified sparse sampling area under the concentration-time curve:its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation.Transplantation,1999,68:55-62.
4Halloran PF,Helms LM,Kung L,et al.The temporal profile of calcineurin inhibition by cyclosporine in vivo.Transplantation,1999,68:1356-1361.
5Sindhi R,LaVia MF,Paulling E,et al.Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporinet rapamycin regimen.Transplantation,2000,69:432-436.
6International Neoral Renal Transplantation Study Group.Randomized,international study of cyclosporine micromulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis.Am J Transplant,2002,2:157-166.
7Citterio F,Scata MC,Borzi MT,et al.C2 single-point sampling to evaluate cyclosporine exposure in long term renal transplant recipients.Transplant Proc,2001,33:3133-3136.
8Macfarlane GD,Scheller DG,Ersfeld DL,et al.Analytical validation of the PRO-Trac II ELISA for the determination of tacrolimus(FK506) in whole blood.Clin Chem,1999,45:1449-1458.
9Mardigyan V,Tchervenkov J,Metrakos P,et al.Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.Clin Ther,2005,27:463-469.
10Johannessen SI,Battino D,Berry DJ,et al.Therapeutic drug monitoring of the newer antiepileptic drugs.Ther Drug Monit,2003,25:347-363.
